

Publication Charges and Reprints

There has been a change in our author billing and reprint ordering system. Publication charges and reprint orders are now handled by Dartmouth Journal Services using a web-based system.

Within the next 24 hours you will receive an e-mail from aubilling.djs@sheridan.com. This e-mail will include a link to an online reprint order form and to an estimate of your publication charges. From this secure website you will be able to review the estimated charges for your article and order reprints. Please log in to this website as soon as possible to ensure that there will be no delay to your article being published.

Please note that this is a change in procedure. If you have questions regarding this change, about the e-mail you will receive, or about the website, please contact aubilling.djs@sheridan.com or call 802-882-1655.

Annotating PDFs using Adobe Acrobat Reader DC

Version 1.7 June 27, 2016

1. Update to Adobe Acrobat Reader DC

The screen images in this document were captured on a Windows PC running Adobe Acrobat Reader DC. Upgrading to the newest version is not always necessary, but it is preferable, and these instructions apply *only* to Adobe Acrobat Reader DC. You can also create annotations using any version of Adobe Acrobat. Adobe Acrobat Reader DC can be downloaded at no cost from <http://get.adobe.com/reader/>

2. What are eProofs?

eProof files are self-contained PDF documents for viewing on-screen and for printing. They contain all appropriate formatting and fonts to ensure correct rendering on-screen and when printing hardcopy. SJS sends eProofs that can be viewed, annotated, and printed using either Adobe Acrobat Reader or Adobe Acrobat.


3. Show the Comment Toolbar

The Comment toolbar isn't displayed by default. To display it, choose View > Tools > Comment > Open.



4. Using the PDF Comments menu

To *insert new text*, place your cursor where you would like to insert the new text, and type the desired text. To *replace* text, highlight the text you would like to replace, and type the desired replacement text. To *delete* text, highlight the text you would like to delete and press the Delete key.

Acrobat and Reader will display a pop-up note based on the modification (e.g., inserted text, replacement text, etc.). To format text in pop-up notes, highlight the text, right click, select Text Style, and then choose a style. A pop-up note can be minimized by selecting the X button inside it. When inserting or replacing text, a  symbol indicates where your comment was inserted, and the comment is shown in the Comments List. **If you do not see the comments list, you are editing the live text instead of adding comments, and your changes are not being tracked. Please make certain to use the Comments feature instead.**

5. Inserting symbols or special characters

An insert symbol feature is not available for annotations, and copying and pasting symbols or non-keyboard characters from Microsoft Word does not always work. Use angle brackets < > to indicate these special characters (e.g., <alpha>, <beta>).

6. Editing near watermarks and hyperlinked text

eProof documents often contain watermarks and hyperlinked text. Selecting characters near these items can be difficult using the mouse. To edit an eProof which contains text in these areas, do the following:

- Without selecting the watermark or hyperlink, place the cursor near the area for editing.
- Use the arrow keys to move the cursor beside the text to be edited.
- Hold down the shift key while simultaneously using arrow keys to select the block of text, if necessary.
- Insert, replace, or delete text, as needed.

7. Reviewing changes


To review all changes, open the Comment menu and the Comment List is displayed.

Note: Selecting a correction in the list highlights the corresponding item in the document, and vice versa.

8. Still have questions?

Try viewing our brief training video at

<https://authorcenter.dartmouthjournals.com/Article/PdfAnnotation>



**Refer to Page 2 for
annotation examples.**

This PDF needs to be proofread and annotated.

Note: these annotations will not actually change the content of the PDF – they just point out the areas where corrections are needed. The actual corrections will be made to the native article files.

1. **Insert Text Tool:** Text needs inserted into this sentence.
2. **Replace Text Tool:** Some of the text in this paragraph needs to be replaced.
3. **Delete Text Tool:** Some of the text in this overly long sentence needs to be deleted.
4. **Sticky Note Tool:** This image needs to be reduced:



tmorse Reply X
Please size this image to a single column
6/24/2016 8:52 AM

A. Inserted text

B. Replaced text

C. Deleted text

D. Sticky Note

Search Comments...

4 Comments A Z ▾ ▾ ...

Page 1 4 ^

tmorse A
T Inserted Text
to be
6/24/2016 8:51 AM

tmorse B
T Replace Text
sentence
6/24/2016 8:51 AM

tmorse C
T Strikethrough Text
6/24/2016 8:50 AM

tmorse D
Please size this image to a single column
6/24/2016 8:52 AM

Type your reply...



Q:1,2,3

Q:4,5,6

Q:7,8,9



Q:10



Q:12



Q:12



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14



Q:14

Choice of Host Cell Line Is Essential for the Functional Glycosylation of the Fc Region of Human IgG1 Inhibitors of Influenza B Viruses

Patricia A. Blundell,* Dongli Lu,† Anne Dell,† Stuart Haslam,† and Richard J. Pleass*

Abs are glycoproteins that carry a conserved *N*-linked carbohydrate attached to the Fc whose presence and fine structure profoundly impacts on their *in vivo* immunogenicity, pharmacokinetics, and functional attributes. The host cell line used to produce IgG has a major impact on this glycosylation, as different systems express different glycosylation enzymes and transporters that contribute to the specificity and heterogeneity of the final IgG-Fc glycosylation profile. In this study, we compare two panels of glycan-adapted IgG1-Fc mutants expressed in either the human endothelial kidney 293-F or Chinese hamster ovary–K1 systems. We show that the types of *N*-linked glycans between matched pairs of Fc mutants vary greatly and in particular, with respect, to sialylation. These cell line effects on glycosylation profoundly influence the ability of the engineered Fcs to interact with either human or pathogen receptors. For example, we describe Fc mutants that potently disrupted influenza B–mediated agglutination of human erythrocytes when expressed in Chinese hamster ovary–K1, but not in human endothelial kidney 293-F cells. *The Journal of Immunology*, 2020, 204: 000–000.

In therapeutic approaches in which the Fc of human IgG1 is critically important, receptor binding and functional properties of the Fc are lost after deglycosylation or removal of the Asn-297 *N*-linked glycosylation attachment site located in the body of the Fc (1–3). More detailed studies into the types of sugars involved in this functionality have shown enhanced FcγRIIIA binding and Ab-dependent cellular cytotoxicity of IgG1 in the absence of fucose (4, 5); enhanced FcγRIIIA binding but rapid clearance from the circulation of IgG1 enriched for oligomannose structures (6–8); and improved solubility, anti-inflammatory activity, thermal stability, and circulatory half-life of terminally sialylated glycans from IgG1 (9–13).

These findings have generated an incentive to modify the existing IgG1 glycans attached to Asn-297, either by

glycoengineering/chemoenzymatic means (12, 14), by mutagenesis programs on the Fc protein backbone that disrupt the protein–Asn-297–carbohydrate interface (15), or by expression in glycosidase-adapted transgenic cell lines (reviewed in Ref. 16). For example, the Food and Drug Administration–approved humanized Ab mogamulizumab, which is used to treat lymphoma and is manufactured in Chinese hamster ovary (CHO) cell lines in which the α(1–6)–fucosyltransferase (*FUT8*) gene is removed, results in an afucosylated IgG1 with enhanced FcγRIIIA-dependent tumor cell killing by Ab-dependent cellular cytotoxicity (17). Although similar approaches have yielded enhanced sialylation of IgG, with zero to moderate improvements in binding to FcγRs (12, 15, 18, 19), these have not led to significant enhancements in binding to inhibitory glycan receptors that are important in controlling unwanted inflammation (19, 20), a finding we and others have attributed to the buried location of the Asn-297–attached glycan within the Fc (21, 22).

Less is known about glycosylation of the receptors to which the IgG1-Fc binds. Although recent studies implicate an active role for Fcγ receptor–associated carbohydrates in fine-tuning Ab–receptor interactions (23, 24), aglycosylated FcγRs expressed in *Escherichia coli* still retain the ability to bind IgG (25–27), bringing into question the exact role of Fcγ receptor glycosylation to IgG1-Fc binding. Similar arguments apply for most of the glycan receptors. For example, DC-SIGN and DC-SIGNR when expressed by *E. coli* still bind Man₉GlcNAc₂ oligosaccharides with high affinity (28). The *N*-linked glycans on glycan receptors are mostly not located near the CRD binding sites but are involved in *cis*-mediated clustering of receptors within the plasma membrane. For example, refolded recombinant *E. coli*–expressed Siglec-5 is sufficient for binding sialylated carbohydrates (29).

We took an alternative approach to enhancing the sialic acid content of the Fc of IgG1 (30, 31) by adding the 18-aa tailpiece from IgM to the C terminus of the IgG1 Fc, into which a cysteine-to-alanine substitution is made at Cys-575, and including an extra *N*-glycosylation site to the N terminus at position Asn-221. The tailpiece also contains an *N*-glycosylation site at Asn-563. This site is known to contain a high proportion of oligomannose

*Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom; and †Department of Life Sciences, Imperial College London, London SW7 2AZ, United Kingdom

ORCID: 0000-0003-3386-5660 (P.A.B.); 0000-0002-5563-679X (S.H.); 0000-0001-7438-8296 (R.J.P.).

Received for publication September 19, 2019. Accepted for publication December 2, 2019.

This work was supported by Pathfinder and Innovator grants from the Wellcome Trust (109469/Z/15/Z and 208938/Z/17/Z) and Institutional Strategic Support Fund 109469/Z/15/Z, 208938/Z/17/Z, and 097830/Z/11/Z from the Wellcome Trust and Medical Research Council Confidence in Concept Award MC_PC_12017, respectively. This work was also supported by Biotechnology and Biological Sciences Research Council Grant BBF0083091 (to A.D. and S.H.).

R.J.P. conceived and designed the overall study. R.J.P., P.A.B., D.L., A.D., and S.H. designed and performed experiments. R.J.P. wrote the manuscript, and all authors commented on drafts and reviewed the final manuscript.

Address correspondence and reprint requests to Prof. Richard J. Pleass, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K. E-mail address: richard.pleass@lstm.ac.uk

The online version of this article contains supplemental material.

Abbreviations used in this article: CHO, Chinese hamster ovary; clec, C-type lectin; GalNAc, *N*-acetylgalactosamine; GlcNAc, *N*-acetylglucosamine; HA, hemagglutinin; HEK, human endothelial kidney; HIA, hemagglutination inhibition assay; MBL, mannose-binding lectin; NA, neuraminidase; PBST, PBS/0.1% Tween 20.

This article is distributed under the terms of the [CC BY 4.0 Unported license](https://creativecommons.org/licenses/by/4.0/).

Copyright © 2020 The Authors

glycans that may explain earlier observations of enhanced binding of IgM to mannose-dependent receptors (30–32). When expressed in CHO-K1 cells, these molecules displayed enhanced binding to the low-affinity Fc γ receptors (Fc γ RIIIA and Fc γ RIIB), and to multiple glycan receptors that control excessive inflammation by IVIG (30, 31, 33). Two such hypersialylated molecules (D221N/C575A and D221N/C309L/N297A/C575A) also bound recombinant hemagglutinin (HA) from influenza A and B viruses and disrupted influenza A–mediated agglutination of human erythrocytes (31).

CHO cell–based systems remain, by far, the most common mammalian cell line used by the pharmaceutical industry; 84% of products are produced in this cell system, and the remaining approved Abs are produced in either NS0 or Sp2/0 cells (34). Although CHO cells account for the largest number of Food and Drug Administration–approved biotherapeutics (34), they do not express α 1,2/3/4 fucosyltransferase and β -1-4-*N*-acetylglucosaminyl-transferase III, which are enzymes expressed in human cells (35). Furthermore, humans have active α 2,6-sialyltransferase. As such, CHO-derived IgG1 Fcs are only sialylated through α 2,3 linkages, whereas both α 2,3 and α 2,6 linkages can be found on human IgG1 Fc (30, 35). Previous detailed *N*-glycan structural analysis has confirmed that CHO cells produce only α 2,3-sialylated *N*-glycans, whereas human endothelial kidney (HEK) cells produce both α 2,3- and α 2,6-sialylated *N*-glycans (36, 37). Most nonhuman mammalian cell lines can also attach *N*-glycolylneuraminic acid. Humans do not have an active CMP–*N*-acetylneuraminic acid hydroxylase and, so, do not attach *N*-

glycolylneuraminic acid, which can elicit immunogenic responses (35), and consequently, nonhuman cell lines are stringently screened to identify clones that produce proteins with desirable glycan profiles (38).

Human cell lines are a promising alternative to nonhuman cell lines, as they possess fully human posttranslational modifications that reduce downstream processing costs and, more importantly, circumvent any risks associated with immunogenicity from non-human glycans. However, human cell lines also have significant limitations, including the capacity to produce sialyl-Lewis^x, which binds to endothelial selectins in areas of inflammation (39). Although this may potentially be favorable for anti-inflammatory therapies (39), the attached sialyl-Lewis^x may also adversely affect the biodistribution and pharmacokinetics of an Fc when used in other clinical contexts, for example, antitumor mAbs. Human cell lines also carry the risk of contamination and forward transmission of human pathogens, in particular viruses, that may explain why CHO-K1 cells are still the preferred cell line used by the pharmaceutical industry (34). These issues led us to compare the functional properties of a panel of Fc mutants generated in CHO-K1 cells with the same set of proteins manufactured by HEK 293-F cells (31).

Materials and Methods

Production of mutants

The generation of glycan mutants in all combinations has been described previously for the hexa-Fc that contains cysteines at both positions 309 and 575 (30). To make the new mutants described in Fig. 1 in which Cys-575











Fc-construct	Heavy chain composition	CHO-K1 PAGE	CHO-K1 HPLC	HEK-293 PAGE	HEK-293 HPLC
IgG1-Fc		monomer	monomer	monomer	monomer
Hexa-Fc		multimer	multimer	multimer	multimer
C575A		monomer >dimer >trimer	monomer >dimer	multimer	multimer
N297A/C575A		monomer >dimer >trimer	monomer >dimer	monomer >dimer	monomer
N563A/C575A		multimer	multimer	multimer	multimer
N297A/N563A/C575A		multimer	multimer	No protein (monomer by blotting)	No protein
D221N/C575A		monomer >dimer	monomer >dimer	multimer	multimer
D221N/N297A/C575A		monomer >dimer	monomer	monomer >dimer >trimer	monomer
D221N/N563A/C575A		multimer	multimer	multimer	monomer & multimer
D221N/N297A/N563A/C575A		multimer	multimer	multimer	monomer & multimer

FIGURE 1. Schematic showing the various HEK 293-F glycan mutants in which Cys-575 is mutated to alanine to create the C575A panel of mutants. Stars indicate the hinge Asn-221, the C γ 2 Asn-297, and the tailpiece Asn-563 glycan sites, respectively.

was mutated to alanine, PCR overlap extension mutagenesis was used with a pair of internal mismatched primers 5'-ACCTGCTTGCTCAACTCT-3'/3'-GGCCAGCTAGCTCAGTAGGCGGTGCCAGC-5' for each plasmid vector coding for a designated glycan modification. The parental plasmids used for these new PCR reactions have been described previously (30). The resulting C575A mutants were then further modified to remove Cys-309 using primer pair 5'-TCACCGTCTTGCACCAGGACT-3'/3'-AGTCCTGGTGCAAGACGGTGA-5' to create the panel of double cysteine knockouts described in Fig. 2. To verify incorporation of the desired mutation and to check for PCR-induced errors, the open reading frames of the new mutants were sequenced on both strands using previously described flanking primers (30). CHO-K1 cells (European Collection of Cell Cultures) were stably transfected with plasmids using FuGENE (Promega), stable cell lines were created, and Fc-secreting clones were expanded and proteins purified as previously described (22, 40). HEK 293-F cells were transiently transfected using the FreeStyle MAX 293 Expression System (Life Technologies) and proteins purified as for CHO-K1 cells.

Size analysis using size exclusion HPLC

An SEC 3000 (300 × 7.8 mm) Column (Beckman Coulter) was set up on a Dionex ICS 3000 HPLC System and pre-equilibrated with 0.2-μm-filtered PBS. Protein samples at concentrations ranging from 0.5 to 1 mg/ml were placed in a precooled autosampler at 4°C, and 10 μl of each was sequentially injected onto the column. Each sample was run for 1.5 column volumes in PBS at a flow rate of 0.25 ml/min. Elution was monitored at 280 and 214 nm. The column was calibrated by running standard proteins (thyroglobulin, bovine IgG, OVA, myoglobin, and cyanocobalamin; Bio-Rad Laboratories) under the same conditions.

Receptor and complement binding assays

Methods describing the binding of mutants to tetrameric human DC-SIGN (Elicityl) and Siglec-1, Siglec-2, and Siglec-3 (Strattech Scientific) have all been described previously (22, 40). The same ELISA protocol was used for Siglec-2, CD23, dectin-1, dectin-2, C-type lectin (clec)-4a, clec-4d, mannose-binding lectin (MBL), and macrophage mannose receptor (Strattech Scientific or Bio-Techne). Binding of C1q has been described previously (22, 40). ELISAs were used to investigate binding of Fc glycan mutants to human FcγRI, FcγRIIA, FcγRIIB, FcγRIIA, and FcγRIIB (Bio-Techne). Receptors were coated down onto ELISA plates (Nunc) in carbonate buffer (pH 9) (Sigma-Aldrich) at 2 μg/ml overnight at 4°C, unless otherwise specified. The plates were blocked in PBS/0.1% Tween 20 (PBST) containing 5% dried skimmed milk. Plates were washed three times in PBST before adding Fc mutant proteins at the indicated concentrations and left at 4°C overnight. Plates were washed as above and incubated for 2 h with 1:500 dilution of an alkaline phosphatase-conjugated goat F(ab')₂ anti-human IgG (The Jackson Laboratory).

Binding of the secondary detecting F(ab')₂ and levels of Ag coating were checked using either anti-human Fc (Fig. 3A) or anti-histidine (Fig. 3B) Abs, respectively, by direct ELISAs to every mutant and/or receptor to ensure potential biases in the detection of binding of different mutants to different receptors could be considered. Because some of the receptors used are not histidine tagged (e.g., DC-SIGN and MBL) or were poorly recognized by the detecting anti-histidine mAb (e.g., dectin-1, dectin-2, clec-4a, and clec-4d), we also checked protein concentrations prior to coating to plates by SDS-PAGE (Fig. 3C).

Plates were washed and developed for 15 min with 100 μl/well of a SIGMAFAST p-Nitrophenyl phosphate solution (Sigma-Aldrich) for alkaline phosphatase-conjugated Abs or with 3,3',5,5'-tetramethylbenzidine dihydrochloride (T3405; Sigma-Aldrich) phosphate-citrate

Fc-construct	Heavy chain composition	CHO-K1 PAGE	CHO-K1 HPLC	HEK-293 PAGE	HEK-293 HPLC
Hexa-Fc		multimer	multimer	multimer	multimer
C309L		multimer	multimer	monomer >multimers	monomer
C309L/C575A		monomer	monomer	monomer >>dimer	monomer
C309L/N297A/C575A		monomer	monomer	monomer	monomer
C309L/N563A/C575A		monomer	multimer	monomer	monomer >dimer >trimer
C309L/N297A/N563A/C575A		monomer	multimer	monomer	monomer >dimer >trimer
D221N/C309L/C575A		monomer	monomer	monomer	monomer
D221N/C309L/N297A/C575A		monomer	monomer	monomer	monomer
D221N/C309L/N563A/C575A		monomer >dimer	multimer	monomer	monomer dimer multimer
D221N/C309L/N297A/N563A/C575A		monomer	monomer multimer >dimer	monomer	monomer dimer multimer

FIGURE 2. Schematic showing the HEK 293-F C575A panel of glycan mutants from Fig. 1 in which the Cys-309 and Leu-310 are changed to leucine and histidine, as found in the native IgG1 Fc sequence to create the C309L/C575A panel of mutants. Stars indicate the hinge Asn-221, the C_γ2 Asn-297, and the tailpiece Asn-563 glycan sites.




FIGURE 3. Characterization of detecting reagents and recombinant receptors. **(A)** Characterization of mutant HEK 293-F Fc proteins by direct ELISA. Mutant Fcs were titrated directly onto plates in carbonate buffer overnight. After blocking in PBST 5% skimmed milk, mutants were detected with a 1:1000 dilution of the alkaline phosphatase-conjugated goat F(ab')₂ anti-human IgG (The Jackson Laboratory) and developed as per methods. **(B)** Characterization of receptor binding by direct ELISA. The receptors were coated down at 0.2 µg per well in carbonate buffer overnight. After blocking in PBST 5% skimmed milk, mutants were detected with 50 ng/ml of an anti-His mAb (MA1-135; Invitrogen) followed by a 1:4000 dilution of a peroxidase-labeled rat anti-mouse κ (1170-05; Southern Biotech). ELISAs were developed as per methods. **(C)** Receptors were visualized by Coomassie blue staining (as per methods). Two micrograms of each receptor was run on 4–12% SDS-PAGE gradient gels under nonreducing conditions. Note that MBL, macrophage mannose receptor, and FcγRIIIB are sold with BSA as a carrier, which clearly masks the receptor bands.

buffer (P4922; Sigma-Aldrich) for HRP-conjugated Abs. Plates were read at 405/450 nm and the data plotted with GraphPad Prism.

Hemagglutination inhibition assay

Native influenza B Hong Kong 5/72 was obtained from Meridian Life Science. To determine the optimal virus-to-erythrocyte ratio, 2-fold virus stock dilutions were prepared in U-shaped 96-well plates (Thermo Fisher Scientific). The same volume of a 1% human O⁺ RBC suspension (Innovative Research) was added to each well and incubated at room temperature for 1 h until erythrocyte pellets had formed. After quantifying the optimal virus-to-erythrocyte concentration (4 HA units), serial 2-fold dilutions of Fc, control IVIG (Gammagard; Baxter Healthcare), and polyclonal goat anti-influenza B (Bio-Rad Laboratories) were prepared, all starting at a concentration of 2 µM, and mixed with 50 µl of the optimal virus dilution. After 30 min incubation at room temperature, 50 µl of the human erythrocyte suspension was added to all wells, and plates were incubated at room temperature for 1 h, after which erythrocyte pellets could be observed in the positive controls and positive samples.

Binding to FcγRs by biacore

Binding to FcγRs was carried out using a Biacore T200 biosensor (GE Healthcare). Recombinantly expressed FcγRS (R&D Systems or Sino Biological) were captured via their histidine tags onto CM5 chips pre-coupled with ~9000 reflective units anti-His Ab (GE Healthcare) using standard amine chemistry. Fc mutants were injected over captured receptors at a flow rate of 20 µl/min, and association and dissociation monitored over indicated time scales before regeneration with two injections of glycine (pH 1.5) and recalibration of the sensor surface with running buffer (10 mM HEPES, 150 mM NaCl [pH 7]). Assays were visualized with Biacore T200 evaluation software v2.0.1.

N-glycomic analysis

N-glycomic analysis was based on previous developed protocol with some modifications (41). Briefly, the N-glycans from 50 µg of each sample was released by incubation with New England Biolabs Rapid PNGase F and isolated from peptides using Sep-Pak C18 cartridges (Waters). The released N-glycans were permethylated prior to MALDI MS analysis. Data

were acquired using a 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosystems) in the positive ion mode. The data were analyzed using Data Explorer (Applied Biosystems) and GlycoWorkbench (42). The proposed assignments for the selected peaks were based on composition together with knowledge of biosynthetic pathways.

Results

Disulfide bonding and glycosylation influence the multimerization states of Fc mutants expressed by HEK 293-F cells

Two panels of glycosylation- and cysteine-deficient mutants previously expressed by CHO-K1 cells were generated in HEK 293-F cells (Figs. 1–3). As observed with CHO-K1 cells, the HEK 293-F cells were capable of making all the mutants to high yields (~30 mg/l) with the exception of the N297A/N563A/C575A mutant, for which we were unable to generate sufficient protein for further work. Generally, all the mutants migrated on SDS-PAGE with the expected molecular weights for their glycosylation or disulfide bonding states (Fig. 4) and as previously described for the same mutants expressed by CHO-K1 cells (30, 31).

In an earlier study with CHO-K1 cells, we demonstrated that a proportion of molecules in which the tailpiece Asn-563 glycan was substituted for alanine ran as multimers in solution when examined by size exclusion HPLC (31). The loss of the bulky Asn-563 glycan exposes hydrophobic amino acid residues in the tailpiece that facilitate noncovalent interactions in solution. Such N563A-dependent multimerization was also observed with mutants expressed by HEK 293-F cells, although the proportion of multimers to monomers (with the notable exception of the N563A/C575A mutant) was generally lower when mutants were made by this cell line (Fig. 5). Clearly, the choice of cell line and,

417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480




FIGURE 4. Characterization of mutant HEK 293-F Fc proteins by SDS-PAGE. **(A)** Cys-309 competent mutants in which Cys-575 is mutated to alanine to create the C575A panel of mutants. Mutants with N563A run as ladderized multimers. Insufficient material was obtained with N297A/N563A/C575A for further analysis. The addition of the N-X-(T/S) glycan sequon to generate N-terminally glycosylated hinges (the D221N series of mutants) did not affect multimerization but rather increased the molecular mass of all mutants. The N297A mutants run as monomers, dimers, and trimers. **(B)** The same mutants as in **(A)** but run under reducing conditions. The D221N/C575A mutant has the largest mass, because it has three glycans attached. The types of glycans attached at Asn-221, Asn-297, and Asn-563 for all the mutants are shown in Fig. 9 and Supplemental Figs 1–4. The decreasing molecular masses seen in the Fc represent the sequential loss of N-linked glycans. **(C)** The same mutants as in **(A)** but stained with Coomassie reagent. **(D)** Substitution of Cys-309 with leucine onto the C575A mutants shown in **(A)** to create the double cysteine knockouts, which all run as monomers. C309L in which Cys-575 is present also multimerizes. **(E)** The same mutants as in **(D)** but run under reducing conditions. Note that the D221N/C309L/C575A mutant with three glycan sites has the largest mass, as seen with the equivalent mutant D221N/C575A in **(A)**. **(F)** Coomassie-stained gel of **(D)**. All proteins were run under either nonreducing **(A)** and **(D)** or reducing conditions **(B)** and **(E)** at 2 μ g protein per lane on 4–8% acrylamide gradient gels, transferred to nitrocellulose, and for **(A)**, **(B)**, **(D)**, and **(E)** blotted with an anti-human IgG Fc (Sigma-Aldrich). **(C)** and **(D)** are stained with Coomassie blue, showing that only Fc proteins are present after purification. For comparison, the same mutants purified from CHO-K1 cells are shown in (24).

consequently, the types of posttranslational modifications dramatically impact on the biophysical properties of these molecules in solution.

Fc glycan mutants expressed by HEK 293-F cells show differences in binding to glycan receptors when compared with CHO-K1 proteins

To determine the impact of the cell line on receptor binding by the two panels of Fc mutants, we investigated their interaction with soluble recombinant glycan receptors by ELISA (Fig. 6, Supplemental Fig. 1). For most of the Fc mutants, including hexa-Fc, C575A, N297A/C575A, D221N/N297A/N563A/C575A, C309L/C575A, D221N/C309L/C575A, D221N/C309L/N297A/C575A, and D221N/C309L/N297A/N563A/C575A, expression in HEK 293-F cells reduced the binding to glycan receptors when compared with equivalent molecules expressed in CHO-K1 cells

(Fig. 6). However, two Fc mutants (D221N/N563A/C575A and D221N/C309L/N573A/C575A) were notable for their enhanced and nonspecific binding to all the glycan receptors investigated when expressed in HEK 293-F cells. Given that both mutants multimerize, although not as efficiently as their equivalents made in CHO-K1 cells (Fig. 5), we attribute this enhanced nonspecific glycan receptor binding not only to increased avidity effects, but also to fine differences in the attached glycan structures (Supplemental Figs. 3, 4). Therefore, the choice of cell line can dramatically impact on the ability of individual Fc mutants to interact with glycan receptors.

545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608




FIGURE 5. Size-exclusion chromatography analysis of individual Fc mutants expressed by either HEK 293-F (black traces) or CHO-K1 cells (gray traces) as published previously (31). Dotted lines indicate the approximate molecular weights of the control 50 kDa Fc fragment (sample 10) or 158 kDa human IgG (sample 9). The m.w. standards (including 670 kDa thyroglobulin) or the indicated numbered mutants were run and eluted from the column as described in the *Materials and Methods*. **(A)** The C575A panel of mutants: 1, D221N/N297A/N563A/C575A; 2, D221N/N563A/C575A; 3, D221N/N297A/C575A; 4, D221N/C575A; 5, N563A/C575A; 6, N297A/C575A; 7, C575A; 8, Hexa-Fc; 9, IVIG (Gammagard); and 10, IgG1-Fc. **(B)** The C309L/C575A panel of mutants: 11, D221N/C309L/N297A/N563A/C575A; 12, D221N/C309L/N563A/C575A; 13, D221N/C309L/N297A/C575A; 14, D221N/C309L/C575A; 15, C309L/N297A/N563A/C575A; 16, C309L/N563A/C575A; 17, C309L/N297A/C575A; 18, C309L/C575A; and 19, C309L.

Fc glycan mutants expressed by HEK 293-F cells show differences in binding FcγRs receptors compared with CHO-K1 cell proteins

Given the observed differences in binding to glycan receptors of the same Fc mutants expressed by two different cell lines, we also tested the impact of cell line on binding to the classical human FcγRs (Fig. 7, Supplemental Fig. 2).

The largest difference observed was the ability of certain HEK-expressed mutants (N563A/C575A, D221N/N563A/C575A, D221N/N297A/N563A/C575A, C309L/N563A/C575A, C309L/N297A/N563A/C575A, and D221N/C309L/N563A/C575A) to bind human FcγRIIA (Arg-167) and FcγRIIIB. This is in stark contrast to the same proteins expressed in CHO-K1 cells, in which not one single mutant from either panel bound the two low-affinity receptors [Fig. 7 and (31)].

To examine the interaction with human FcγRIIA (Arg-167) and FcγRIIIB in more detail, we tested binding of two of these mutants (C309L/N563A/C575A and D221N/C309L/N563A/C575A) to FcγRIIIB and FcγRIIA (Arg-167), respectively, by surface plasmon resonance analysis (Fig. 8, Tables I, II). Both mutants displayed slower apparent off rates compared with the control IgG1-Fc monomer, consistent with avidity effects either through binding to multiple immobilized FcγR molecules or rebinding effects (Fig. 8). Therefore, the choice of cell line impacts on the ability of individual Fc mutants to interact with FcγRs and, in particular, FcγRIIA (Arg-167) and FcγRIIIB.

Fc glycan mutants expressed by HEK 293-F cells show improved binding to human C1q

An important functional and safety attribute for therapeutic administration of Fc fragments is their ability to bind C1q and, thus, initiate the classical pathway of complement activation. Binding of C1q was assessed by ELISA to selected mutants expressed from each cell line (Fig. 9). Mutants D221N/C575A, D221N/C309L/C575A, C309L/N297A/N563A/C575A, and C309L/N563A/C575A expressed in HEK 293-F cells showed improved binding to C1q, compared with their counterparts expressed in CHO-K1 cells, and no change in binding in either direction was observed for IgG1-Fc, D221N/N563A/C575A, D221N/N297A/C575A, D221N/C309L/N297A/C575A, D221N/C309L/N297A/N563A/C575A, and C309L/N297A/C575A (Fig. 9).

Both the D221N/C575A and D221N/C309L/N297A/C575A mutants from CHO-K1 cells have been shown previously to block influenza-mediated hemagglutination [(24) and Figs. 10–12, below], and thus, D221N/C575A expressed in HEK 293-F cells that binds C1q may not be favored for clinical development over the same molecule expressed by CHO-K1 cells (35).

Fc glycan mutants expressed in HEK 293-F cells have more complex glycosylation profiles than the equivalent mutants expressed in CHO-K1 cells

The structure of the *N*-glycans on the Fc of IgG Abs has been shown to influence multiple receptor interactions (3, 43, 44). Unlike the relatively simple glycosylation of the Fc mutants previously described for CHO cells (30, 31), HEK cells are capable of producing more complex *N*-glycan structures on their glycoproteins (45).

673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736




FIGURE 6. Shading matrix showing the differential binding of HEK 293-F or CHO-K1 mutant proteins to recombinant glycan receptors. Results from at least two independent ELISA experiments are expressed as fold change (up or down) with respect to the internal IgG1 Fc control run on each plate. Standalone ELISA data are provided in the Supplemental Fig. 1. White boxes, not tested.

We investigated the nature of the *N*-glycans on the two panels of glycosylation- and cysteine-deficient mutants by MALDI-TOF mass spectrometry-based glycomic analysis (complete dataset for both panels of mutants provided in Supplemental Figs. 3, 4). A core-fucosylated biantennary structure without antennary galactosylation, *m/z* 1835 (GlcNAc₄Man₃Fuc₁), is the base peak of

spectra from all IgG1-Fc mutants produced by HEK cells (Fig. 10, Supplemental Figs. 3, 4).

An indication of the types of glycans attached to either Asn-221, Asn-297, or Asn-563 could be determined using both the C575A or the C309L/C575A panels of mutants. For example, only *N*-glycans attached to Asn-297 are available for sampling in either the N563A/C575A or C309L/N563A/C575A, mutants that, therefore,




FIGURE 7. Shading matrix showing the differential binding of HEK 293-F or CHO-K1 mutant proteins to rFc γ receptors. Results from at least two independent ELISA experiments are expressed as fold change (up or down) with respect to the internal IgG1 Fc control run on each plate. Standalone ELISA data are provided in the Supplemental Fig. 2.

737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800




FIGURE 8. Surface plasmon resonance analysis. Binding of selected mutants to human Fc γ RIIIB (A–C) or Fc γ RIIA-Arg¹⁶⁷ (D–F) by Biacore. Control IgG1 Fc (A and D) is compared with C309L/N563A/C575A (B and E) and D221N/C309L/N563A/C575A (C and F). Curves show equivalent molar concentrations doubled diluted from the highest concentration shown. Because of the varying stoichiometry of the molecules shown (as seen in Figs. 3 and 4), an accurate determination of the interaction kinetics is not possible, and K_D values are calculated assuming a monomeric Fc. Summary tables for the kinetic values obtained from duplicate experiments are shown in Table I. Binding was to receptors sourced from R&D Systems (Bio-Techne).

also allow the contribution of disulfide bonding to glycosylation at Asn-297 to be elucidated.

In these mutants, *N*-glycosylation of Asn-297 is dominated by core-fucosylated biantennary glycans (m/z 1835 and 2040) with varied galactosylation levels (Gal₀₋₂GlcNAc₄Man₃Fuc₁), and a Man₅GlcNAc₂ (m/z 1579) oligomannose structure is also observed (Fig. 10B). The Asn-563 *N*-glycans are much more complex and heterogeneous. Abundant truncated structures at m/z 2081 and 2285 have potentially terminal *N*-acetylglucosamine (GlcNAc) or *N*-acetylgalactosamine (GalNAc) (Fig. 10A). Antennal fucosylation and sialylation are also observed on structures that can assemble sialyl-*N*-acetylglucosamine, sialyl-Lewis x/a, fucosylated LacdiNAc, or sialylated LacdiNAc (GalNAc-GlcNAc), for example, peak m/z 4039 (NeuAc₂Gal₄GlcNAc₆Man₃Fuc₂). The presence of m/z 2674 (GalNAc₂GlcNAc₄Man₃Fuc₃) in the N297A/C575A mutant confirms the presence of fucosylated LacdiNAc epitopes on the Asn-563 site. Thus, glycosylation at Asn-563 is different to that seen from CHO-K1 cells that assemble less-diverse structures without antennal fucosylation and, therefore, more terminal sialyl-*N*-acetylglucosamine (30, 31). In agreement with earlier work (32) and irrespective of the cell line used for their manufacture, a high proportion of oligomannose structures can be found attached to Asn-563 (e.g., in the C309L/N297A/C575A mutant) (Supplemental Fig. 4), although these were not observed in the corresponding N297A/C575A mutant (Fig. 10A). We do not have an obvious explanation for these Asn-563 differences, although the presence of redox-sensitive cysteines are known to modify protein glycosylation in other systems (46).

The Asn-221 site is mainly composed of biantennary complex structures (Fig. 10C). Excluding the base peak, four structures in the C575A background (m/z 2081, 2285, 2459, and 2646) or five

structures in the C309L/C575A background (2081, 2285, 2459, 2489, and 2734) could form LacdiNAc antenna (GalNAc-GlcNAc). Antennal fucosylation and sialylation is also observed (Fig. 10C, Supplemental Fig. 4).

In summary, these data show that the types of glycans attached to either Asn-221, Asn-297, or Asn-563 are different between cell lines but are not grossly affected by disulfide bonding.

Fc glycan mutants expressed in HEK 293-F cells are less sialylated than the equivalent mutants expressed in CHO-K1 cells

Site-specific levels of sialylation were semiquantitatively assessed for both panels of mutants and compared with levels seen in the equivalent mutants expressed in CHO-K1 cells (Fig. 11). Although levels of sialylated glycans attached at positions Asn-297 (the N563A/C575A mutant) and Asn-563 (the N297A/C575A mutant) are similar for both cell lines (Fig. 11), a marked reduction in

Table I. Summary for kinetic data obtained for human Fc γ RIIIB (CD16B) from SPR analysis

Protein	K_D (M) ^a	R_{MAX}	χ^2 (RU ²)
Irrelevant IgG1	1.34×10^{-5}	102.6	0.425
C309L/N563A/C575A	1.38×10^{-6}	98.7	9.7
	2.23×10^{-6}	113.9	8.39
D221N/C309L/N563A/C575A	1.53×10^{-6}	80.6	3.7
	2.87×10^{-6}	95.5	3.95

^aProteins were run at the milligram per milliliter equivalent of the Fc control. Curves on each graph in Fig. 8 are approximate equivalent molar concentrations assuming a monomeric Fc. K_D values are calculated assuming a monomeric Fc. Numbers in brackets indicate experiment number. SPR, surface plasmon resonance.

929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992

Table II. Summary for kinetic data obtained for human FcγRIIA_{167Arg} (CD32A) from SPR analysis

Protein	K _D (M) ^a	R _{MAX}	χ ² (RU ²)
Irrelevant IgG1	5.98 × 10 ⁻⁶	190.1	11.8
C309L/N563A/C575A	6.20 × 10 ⁻⁷	131.9	13.3
	1.96 × 10 ⁻⁶	61.2	2.62
D221N/C309L/N563A/C575A	6.62 × 10 ⁻⁷	92.9	1.38
	1.75 × 10 ⁻⁶	34.1	0.49

^aProteins were run at the milligram per milliliter equivalent of the Fc control. Curves on each graph in Fig. 8 are approximate equivalent molar concentrations assuming a monomeric Fc. K_D values are calculated assuming a monomeric Fc. Numbers in brackets indicate experiment number. SPR, surface plasmon resonance.

levels of sialylated glycans at Asn-221 (the D221N/N297A/N563A/C575A mutant) is observed when this mutant is expressed in HEK cells (2.8% against 81.8% in CHO; Fig. 11). Removal of Asn-297 generally enhanced levels of sialylation at both Asn-221 and Asn-563, irrespective of the cell line or the multimerization state of the proteins (e.g., compare N297A/C575A versus C575A and C309L/N297A/C575A versus C309L/C575A) (Fig. 11). The choice of cell line, therefore, dramatically affects the overall levels of sialylation at individual N-linked attachment sites within the glycan-modified Fc variants.

Asn-221-containing mutants are poor inhibitors of hemagglutination by influenza virus when expressed in HEK 293-F cells

To test if the choice of cell line affected the functionality of the two panels of mutant Fcs, we used the World Health Organization hemagglutination inhibition assay (HIA) to quantify the inhibitory

titers for each mutant against an influenza B virus (Fig. 12). As shown previously with an avian influenza A (H1N1) (31), mutants containing Asn-221 hinge-attached glycans, and, in particular, the D221N/C309L/N297A/C575A mutant, prevented hemagglutination by an influenza B virus at concentrations as low as 30 nM, an 8-fold improvement over equimolar IVIG or polyclonal anti-influenza B antisera (Fig. 12). In stark contrast, the same mutants expressed by HEK 293-F cells were unable to inhibit hemagglutination by either influenza A (data not shown) or influenza B virus (Fig. 12). This shows that the functional potential of individual glycan-modified Fc mutants is dependent on the choice of cell line used for their manufacture.

Discussion

We have shown using CHO-K1 cells that the structure and effector function of human IgG1-Fc can be profoundly altered by the addition or removal of N-linked glycosylation (30, 31). For example, we could show that Fc fragments containing complex biantennary glycans attached to both the N- and C-terminal ends of the Fc could inhibit influenza A-mediated agglutination of human erythrocytes (31). The aim of the current study was to reveal possible variation in functional glycosylation related to differences in two host cell lines, CHO-K1 and HEK 293-F, particularly as Abs and Fc fusions are the fastest growing therapeutic class in the pharmaceutical industry (34, 47, 48).

Two intriguing aspects of N-linked glycosylation are relevant to this study. First, the differential binding seen to human glycan (Fig. 6) and Fcγ (Fig. 7) receptors between the same mutants expressed by two different cell lines. These differentially manufactured mutants now need to be compared in relevant in vivo




FIGURE 9. Binding of selected C575A and C309L/C575A mutants to complement component C1q. Mutants expressed in HEK 293-F cells bind human C1q better than the equivalent mutants expressed in CHO-K1 cells. Compare for example the D221N/C575 mutant made in CHO-K1 cells (open triangle) against the same mutant made in HEK 293-F cells (open circle) and compared on the same plate. Error bars represent SD around the mean value (n = 2 independent ELISA experiments).

F12 1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120




FIGURE 10. MALDI-TOF MS profiles of permethylated *N*-glycans from the N297A/C575A (Asn-563) (A), N563A/C575A (Asn-297) (B), and D221N/N297A/N563A/C575A (Asn-221) (C) Fc glycan mutants expressed in HEK 293-F cells. Linkage-determined monosaccharides are positioned above the bracket on a structure. Poly-hexose contaminants are highlighted with crosses. The data were acquired in the positive ion mode to observe $[M+Na]^+$ molecular ions. All the structures are based on composition and knowledge of *N*-glycan biosynthetic pathways. Structures shown outside a bracket have not had their antenna location unequivocally defined.

disease models in which the Fc is therapeutically useful, given that differential sialic acid linkages, α 2,6 and α 2,3, are known to impact on the anti-inflammatory properties of the Fc (49, 50). Such nuanced glycosylation may also explain why the therapeutic efficacy of molecules generated by different expression systems, and subsequently tested in different animal models, do not always translate to efficacy in human studies (51).

Second, we have studied the exquisite impact of the host cell line on the efficacy of sialylated Fcs to inhibit influenza viruses (Fig. 12). One possible explanation is that overall sialylation levels for all the influenza blocking mutants, in particular the D221N/C309L/N297A/C575A mutant, are \sim 5-fold lower when expressed by HEK 293-F cells (Fig. 11). However, overall level of sialylation is not the only possible explanation for the relative efficacy of the CHO-K1 mutants in inhibiting influenza virus

hemagglutination, as the CHO-K1-expressed D221N/C575A mutant also contained \sim 5-fold-less sialylation than the D221N/C309L/N297A/C575A mutant made in the same cell line (Fig. 11). This indicates that the fine specificity (e.g., α 2,3 versus α 2,6 linkages) of these sialylated glycans may also be a contributing factor to their efficacy.

As demonstrated previously for influenza A (31), binding and inhibition of influenza B viruses is stronger with mutants containing Asn-221 and, in particular, by the monomeric mutant D221N/C309L/N297A/C575A in which the N- and C-terminal sialylated sugars are spaced \sim 60 Å apart [Fig. 12 and (31)]. Recent biophysical studies with alternative glycan-decorated scaffolds have shown that \sim 1000-fold enhancements over monovalent binding to HA can be achieved with only two sialylated ligands, provided the sugars are arranged 50–100 Å apart (52, 53).

1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312

1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376




FIGURE 11. Semiquantitative determination of sialylated (black) against neutral (gray) glycans from the C575A and C309L/C575A mutants expressed in CHO-K1 or HEK 293-F cells. Values shown in brackets under the names of each mutant show percentage-sialylated structures as determined from summed intensities.

As observed with Fc-multimerizing mutants from panel 1, no additional benefit with respect to virus neutralization was gained with larger, more complex sialylated structures (Fig. 12, and as

seen with the D221N/N297A/N563A/C575A and D221N/N563A/C575A mutants). The lack of monomers observed for both these mutants when expressed by HEK cells (Fig. 5A) may offer a




FIGURE 12. Impact of Fc glycosylation on influenza B-mediated hemagglutination. Mutant Fcs manufactured in either HEK 293-F or CHO-K1 cells were compared with equimolar concentration of IVIG or polyclonal anti-influenza B Abs at inhibiting virus-mediated agglutination of human erythrocytes. 1, L309C; 2, C575A; 3, N297A/C575A; 4, N563A/C575A; 5, no protein; 6, D221N/C575A; 7, D221N/N297A/C575A; 8, D221N/N563A/C575A; 9, D221N/N297A/N563A/C575A; 10, C309L; 11, C309L/C575A; 12, C309L/N297A/C575A; 13, C309L/N573A/C575A; 14, C309L/N297A/N563A/C575A; 15, D221N/C309L/C575A; 16, D221N/C309L/N297A/C575A; 17, D221N/C309L/N563A/C575A; and 18, D221N/C309L/N297A/N563A/C575A. A constant amount of influenza B Hong Kong 5/72 virus was incubated with titrated amounts of the Fc glycan mutants and added to human O⁺ erythrocytes that were then allowed to sediment at room temperature for 1 h. Nonagglutinated RBCs form a small halo (*n* = 3 independent experiments).

simpler explanation for why the HEK-expressed proteins did not inhibit influenza viruses in the HIA, yet their equivalents expressed by CHO-K1 cells and that contain a large proportion of monomers did partially inhibit hemagglutination by virus (Fig. 12). As multimers, neither of the sialylated Fc-capping glycans (Asn-221 or Asn-563) may be optimally available for interactions with HA as they are with mutants that uniquely exist as monomers (e.g., D221N/C309L/N297A/C575A) (30, 31).

We do not yet know if sialylated Fcs are susceptible to cleavage by the viral neuraminidase (NA). Although a decoy for NA may be a therapeutically attractive strategy (54), we have not observed a direct decay in the HIA after prolonged incubation. This suggests that the high specific avidity of these molecules for HA may reduce their susceptibility to NA, a hypothesis that fits with the relatively low efficiency of NA ($k_{\text{cat}} = 30\text{--}155\text{ s}^{-1}$), together with the asymmetric distribution of NA in relation to HA on the surface of filamentous influenza viruses (55–57).

To be useful compounds when administered intranasally, or as an aerosol, the sialylated Fc needs to outcompete sialylated mucins that viruses use through ratchet-like interactions with HA and NA to migrate to the underlying respiratory epithelium (55). Of the 15 known human mucins in the human lung, only MUC5 has been shown to protect from influenza (58, 59). Most sialic acid found on human mucins are *O*-glycosylated, and where *N*-linked attachments do occur, these are mostly sialylated via α 2,6-linkages (59). Thus, we were surprised that none of the Fc leads inhibited influenza A (H1N1 propagated in hen eggs) or influenza B (Hong Kong 5/72 propagated in Madin–Darby canine kidney cells) agglutination of human O^+ erythrocytes when manufactured by HEK 293-F cells that attach more human type α 2,6-linked sialic acid (Fig. 10).

The apparent importance of α 2,3-linked *N*-glycans to inhibition of both influenza A and B by the CHO-K1 Fc mutants indicates that viruses can evolve away from inhibition by mucus whose predominant *O*-linked glycans are mostly α 2,6-linked. Our working hypothesis is that HEK-expressed compounds may therefore inhibit influenza viruses that circulate in human populations or that are propagated in cell lines that attach more human-like α 2,6-linked sialic acid.

Consequently, by careful consideration of the cell line used in their manufacture, new glycan repertoires with desirable binding attributes and functionality can be imparted to the therapeutically attractive Fc molecule.

Acknowledgments

We thank Abzena PLC for running the surface plasmon resonance analysis and Dr. Mark Wilkinson for running size exclusion HPLC samples.

Disclosures

R.J.P. and P.A.B. declare that work discussed within is subject to ongoing patent applications.

References

- Lund, J., N. Takahashi, J. D. Pound, M. Goodall, and R. Jefferis. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. *J. Immunol.* 157: 4963–4969.
- Wright, A., and S. L. Morrison. 1994. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. *J. Exp. Med.* 180: 1087–1096.
- Pincetic, A., S. Bournazos, D. J. DiLillo, J. Maamary, T. T. Wang, R. Dahan, B.-M. Fiebiger, and J. V. Ravetch. 2014. Type I and type II Fc receptors regulate innate and adaptive immunity. *Nat. Immunol.* 15: 707–716.

- Shields, R. L., J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. A. Weikert, and L. G. Presta. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. *J. Biol. Chem.* 277: 26733–26740.
- Shinkawa, T., K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J. Biol. Chem.* 278: 3466–3473.
- Kanda, Y., T. Yamada, K. Mori, A. Okazaki, M. Inoue, K. Kitajima-Miyama, R. Kuni-Kamochi, R. Nakano, K. Yano, S. Kakita, et al. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. [Published erratum appears in 2007 *Glycobiology* 17: 1030.] *Glycobiology* 17: 104–118.
- Yu, M., D. Brown, C. Reed, S. Chung, J. Lutman, E. Stefanich, A. Wong, J. P. Stephan, and R. Bayer. 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. *MAbs* 4: 475–487.
- Goetze, A. M., Y. D. Liu, Z. Zhang, B. Shah, E. Lee, P. V. Bondarenko, and G. C. Flynn. 2011. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. *Glycobiology* 21: 949–959.
- Debré, M., M. C. Bonnet, W. H. Fridman, E. Carosella, N. Philippe, P. Reinert, E. Vilmer, C. Kaplan, J. L. Teillaud, and C. Griscelli. 1993. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. *Lancet* 342: 945–949.
- Liu, L. 2015. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. *J. Pharm. Sci.* 104: 1866–1884.
- Zhang, G., C. A. Massaad, T. Gao, L. Pillai, N. Bogdanova, S. Ghauri, and K. A. Sheikh. 2016. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury. *Exp. Neurol.* 282: 49–55.
- Washburn, N., I. Schwab, D. Ortiz, N. Bhatnagar, J. C. Lansing, A. Medeiros, S. Tyler, D. Mekala, E. Cochran, H. Sarvaiya, et al. 2015. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. [Published erratum appears in 2015 *Proc. Natl. Acad. Sci. USA* 112: E4339.] *Proc. Natl. Acad. Sci. USA* 112: E1297–E1306.
- Anthony, R. M., F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson, and J. V. Ravetch. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. *Science* 320: 373–376.
- Dekkers, G., R. Plomp, C. A. M. Koeleman, R. Visser, H. H. von Horsten, V. Sandig, T. Rispens, M. Wührer, and G. Vidarsson. 2016. Multi-level glycoengineering techniques to generate IgG with defined Fc-glycans. *Sci. Rep.* 6: 36964.
- Yu, X., K. Baruah, D. J. Harvey, S. Vasiljevic, D. S. Alonzi, B. D. Song, M. K. Higgins, T. A. Bowden, C. N. Scanlan, and M. Crispin. 2013. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. *J. Am. Chem. Soc.* 135: 9723–9732.
- Cymer, F., H. Beck, A. Rohde, and D. Reusch. 2018. Therapeutic monoclonal antibody N-glycosylation - structure, function and therapeutic potential. *Biologicals* 52: 1–11.
- Mahajan, V. S., and K. Tobinai. 2017. Mogamulizumab for the treatment of T-cell lymphoma. [Published erratum appears in 2017 *Expert Opin. Biol. Ther.* 17: 1145–1153.] *Expert Opin. Biol. Ther.* 17: 1145–1153.
- Huang, W., J. Giddens, S. Q. Fan, C. Toonstra, and L. X. Wang. 2012. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. *J. Am. Chem. Soc.* 134: 12308–12318.
- Yu, X., S. Vasiljevic, D. A. Mitchell, M. Crispin, and C. N. Scanlan. 2013. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. *J. Mol. Biol.* 425: 1253–1258.
- Mahajan, V. S., and S. Pillai. 2016. Sialic acids and autoimmune disease. *Immunol. Rev.* 269: 145–161.
- Subedi, G. P., Q. M. Hanson, and A. W. Barb. 2014. Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient Fc gamma RIIIa binding. *Structure* 22: 1478–1488.
- Czajkowsky, D. M., J. T. Andersen, A. Fuchs, T. J. Wilson, D. Mekhaieil, M. Colonna, J. He, Z. Shao, D. A. Mitchell, G. Wu, et al. 2015. Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications. *Sci. Rep.* 5: 9524.
- Cambay, F., O. Henry, Y. Durocher, and G. De Crescenzo. 2019. Impact of N-glycosylation on Fc gamma receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions. *MAbs* 11: 435–452.
- Patel, K. R., J. T. Roberts, G. P. Subedi, and A. W. Barb. 2018. Restricted processing of CD16a/Fc gamma receptor IIIa N-glycans from primary human NK cells impacts structure and function. *J. Biol. Chem.* 293: 3477–3489.
- Sondermann, P., and U. Jacob. 1999. Human Fc gamma receptor IIb expressed in *Escherichia coli* reveals IgG binding capability. *Biol. Chem.* 380: 717–721.
- Sondermann, P., R. Huber, V. Oosthuizen, and U. Jacob. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gamma RIII complex. *Nature* 406: 267–273.
- Maenaka, K., P. A. van der Merwe, D. I. Stuart, E. Y. Jones, and P. Sondermann. 2001. The human low affinity Fc gamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. *J. Biol. Chem.* 276: 44898–44904.

- 1505 28. Mitchell, D. A., A. J. Fadden, and K. Drickamer. 2001. A novel mechanism of
1506 carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR.
1507 Subunit organization and binding to multivalent ligands. *J. Biol. Chem.* 276:
1508 28939–28945.
- 1509 29. Barb, A. W., X. Wang, and J. H. Prestegard. 2013. Refolded recombinant Siglec5
1510 for NMR investigation of complex carbohydrate binding. *Protein Expr. Purif.* 88:
1511 183–189.
- 1512 30. Blundell, P. A., N. P. L. Le, J. Allen, Y. Watanabe, and R. J. Pleass. 2017. En-
1513 gineering the fragment crystallizable (Fc) region of human IgG1 multimers and
1514 monomers to fine-tune interactions with sialic acid-dependent receptors. *J. Biol.*
1515 *Chem.* 292: 12994–13007.
- 1516 31. Blundell, P. A., D. Lu, M. Wilkinson, A. Dell, S. Haslam, and R. J. Pleass. 2019.
1517 Insertion of N-terminal hinge glycosylation enhances interactions of the Fc re-
1518 gion of human IgG1 monomers with glycan-dependent receptors and blocks
1519 hemagglutination by the influenza virus. *J. Immunol.* 202: 1595–1611.
- 1520 32. Arnold, J. N., M. R. Wormald, D. M. Suter, C. M. Radcliffe, D. J. Harvey,
1521 R. A. Dwek, P. M. Rudd, and R. B. Sim. 2005. Human serum IgM glycosylation:
1522 identification of glycoforms that can bind to mannan-binding lectin. *J. Biol.*
1523 *Chem.* 280: 29080–29087.
- 1524 33. Spence, S., M. K. Greene, F. Fay, E. Hams, S. P. Saunders, U. Hamid,
1525 M. Fitzgerald, J. Beck, B. K. Bains, P. Smyth, et al. 2015. Targeting Siglecs with
1526 a sialic acid-decorated nanoparticle abrogates inflammation. *Sci. Transl. Med.* 7:
1527 303ra140.
- 1528 34. Walsh, G. 2018. Biopharmaceutical benchmarks 2018. *Nat. Biotechnol.* 36:
1529 1136–1145.
- 1530 35. Goh, J. B., and S. K. Ng. 2018. Impact of host cell line choice on glycan profile.
1531 *Crit. Rev. Biotechnol.* 38: 851–867.
- 1532 36. North, S. J., H. H. Huang, S. Sundaram, J. Jang-Lee, A. T. Etienne, A. Trollope,
1533 S. Chalabi, A. Dell, P. Stanley, and S. M. Haslam. 2010. Glycomics profiling of
1534 Chinese hamster ovary cell glycosylation mutants reveals N-glycans of a novel
1535 size and complexity. *J. Biol. Chem.* 285: 5759–5775.
- 1536 37. Wong, M. Y., K. Chen, A. Antonopoulos, B. T. Kasper, M. B. Dewal,
1537 R. J. Taylor, C. A. Whittaker, P. P. Hein, A. Dell, J. C. Genereux, et al. 2018.
1538 XBP1s activation can globally remodel N-glycan structure distribution patterns.
1539 *Proc. Natl. Acad. Sci. USA* 115: E10089–E10098.
- 1540 38. Ghaderi, D., R. E. Taylor, V. Padler-Karavani, S. Diaz, and A. Varki. 2010.
1541 Implications of the presence of N-glycolylneuraminic acid in recombinant
1542 therapeutic glycoproteins. *Nat. Biotechnol.* 28: 863–867.
- 1543 39. Mulligan, M. S., R. L. Warner, C. W. Rittershaus, L. J. Thomas, U. S. Ryan,
1544 K. E. Foreman, L. D. Crouch, G. O. Till, and P. A. Ward. 1999. Endothelial
1545 targeting and enhanced antiinflammatory effects of complement inhibitors pos-
1546 sessed sialyl Lewisx moieties. *J. Immunol.* 162: 4952–4959.
- 1547 40. Mekhaieil, D. N. A., D. M. Czajkowsky, J. T. Andersen, J. Shi, M. El-Faham,
1548 M. Doenhoff, R. S. McIntosh, I. Sandlie, J. He, J. Hu, et al. 2011. Polymeric
1549 human Fc-fusion proteins with modified effector functions. *Sci. Rep.* 1: 124.
- 1550 41. North, S. J., J. Jang-Lee, R. Harrison, K. Canis, M. N. Ismail, A. Trollope,
1551 A. Antonopoulos, P. C. Pang, P. Grassi, S. Al-Chalabi, et al. 2010. Mass spec-
1552 trometric analysis of mutant mice. *Methods Enzymol.* 478: 27–77.
- 1553 42. Ceroni, A., K. Maass, H. Geyer, R. Geyer, A. Dell, and S. M. Haslam. 2008.
1554 GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of
1555 glycans. *J. Proteome Res.* 7: 1650–1659.
- 1556 43. Massoud, A. H., M. Yona, D. Xue, F. Chouiali, H. Alturaihi, A. Ablona,
1557 W. Mourad, C. A. Piccirillo, and B. D. Mazer. 2014. Dendritic cell immunore-
1558 ceptor: a novel receptor for intravenous immunoglobulin mediates induction of
1559 regulatory T cells. *J. Allergy Clin. Immunol.* 133: 853–63.e5.
- 1560 44. S  it  , J. F., D. Cornec, Y. Renaudineau, P. Youinou, R. A. Mageed, and
1561 S. Hillion. 2010. IVIg modulates BCR signaling through CD22 and promotes
1562 apoptosis in mature human B lymphocytes. *Blood* 116: 1698–1704.
- 1563 45. Lo, C. Y., A. Antonopoulos, R. Gupta, J. Qu, A. Dell, S. M. Haslam, and
1564 S. Neelamegham. 2013. Competition between core-2 GlcNAc-transferase and
1565 ST6GalNAc-transferase regulates the synthesis of the leukocyte selectin ligand
1566 on human P-selectin glycoprotein ligand-1. *J. Biol. Chem.* 288: 13974–13987.
- 1567 46. Capellari, S., S. I. A. Zaidi, C. B. Urig, G. Perry, M. A. Smith, and
1568 R. B. Petersen. 1999. Prion protein glycosylation is sensitive to redox change. *J.*
1569 *Biol. Chem.* 274: 34846–34850.
- 1570 47. Mastrangeli, R., W. Palinsky, and H. Bierau. 2019. Glycoengineered antibodies:
1571 towards the next-generation of immunotherapeutics. *Glycobiology* 29: 199–210.
- 1572 48. Czajkowsky, D. M., J. Hu, Z. Shao, and R. J. Pleass. 2012. Fc-fusion proteins:
1573 new developments and future perspectives. *EMBO Mol. Med.* 4: 1015–1028.
- 1574 49. Sondermann, P., A. Pincetic, J. Maamary, K. Lammens, and J. V. Ravetch. 2013.
1575 General mechanism for modulating immunoglobulin effector function. *Proc.*
1576 *Natl. Acad. Sci. USA* 110: 9868–9872.
- 1577 50. Anthony, R. M., F. Wermeling, M. C. I. Karlsson, and J. V. Ravetch. 2008.
1578 Identification of a receptor required for the anti-inflammatory activity of IVIG.
1579 *Proc. Natl. Acad. Sci. USA* 105: 19571–19578.
- 1580 51. Antonopoulos, A., S. J. North, S. M. Haslam, and A. Dell. 2011. Glycosylation
1581 of mouse and human immune cells: insights emerging from N-glycomics anal-
1582 yses. *Biochem. Soc. Trans.* 39: 1334–1340.
- 1583 52. Bandlow, V., D. Lauster, K. Ludwig, M. Hilsch, V. Reiter-Scherer, J. P. Rabe,
1584 C. B  tcher, A. Herrmann, and O. Seitz. 2019. Sialyl-LacNAc-PNA-DNA con-
1585 catamers by rolling-circle amplification as multivalent inhibitors of influenza A
1586 virus particles. *ChemBiochem* 20: 159–165.
- 1587 53. Bandlow, V., S. Liese, D. Lauster, K. Ludwig, R. R. Netz, A. Herrmann, and
1588 O. Seitz. 2017. Spatial screening of hemagglutinin on influenza A virus particles:
1589 sialyl-LacNAc displays on DNA and PEG scaffolds reveal the requirements for
1590 bivalency enhanced interactions with weak monovalent binders. *J. Am. Chem.*
1591 *Soc.* 139: 16389–16397.
- 1592 54. Ernst, B., and J. L. Magnani. 2009. From carbohydrate leads to glycomimetic
1593 drugs. *Nat. Rev. Drug Discov.* 8: 661–677.
- 1594 55. Vahey, M. D., and D. A. Fletcher. 2019. Influenza A virus surface proteins are
1595 organized to help penetrate host mucus. *eLife* 8: e43764.
- 1596 56. Waldmann, M., R. Jirrmann, K. Hoelscher, M. Wienke, F. C. Niemeyer,
1597 D. Rehders, and B. Meyer. 2014. A nanomolar multivalent ligand as entry in-
1598 hibitor of the hemagglutinin of avian influenza. *J. Am. Chem. Soc.* 136: 783–788.
- 1599 57. Gao, Z., M. Niikura, and S. G. Withers. 2017. Ultrasensitive fluorogenic reagents
1600 for neuraminidase titration. *Angew. Chem. Int. Ed. Engl.* 56: 6112–6116.
- 1601 58. Roy, M. G., A. Livraghi-Butrico, A. A. Fletcher, M. M. McElwee, S. E. Evans,
1602 R. M. Boerner, S. N. Alexander, L. K. Bellinghausen, A. S. Song, Y. M. Petrova,
1603 et al. 2014. Muc5b is required for airway defence. *Nature* 505: 412–416.
- 1604 59. Zanin, M., P. Bavisar, R. Webster, and R. Webby. 2016. The interaction be-
1605 tween respiratory pathogens and mucus. *Cell Host Microbe* 19: 159–168.
- 1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

1

- 1—Please confirm or amend the changes made to the grant footnote; in particular, please confirm that “MRC” has been expanded correctly in the footnote or amend as needed.
- 2—Please confirm Key Points for your article: Choice of cell line is critical for functional glycosylation of human IgG1-Fc.
Sialylated IgG1-Fc monomers block influenza B only when made by CHO-K1 cells.
- 3—Please confirm that the listed ORCID IDs are correct. Additional ORCID IDs cannot be added at this stage.
- 4—Please verify that the title, footnotes, author names, and affiliations are correct as set. In particular, please note that Fc is used without expansion in the journal, so Fraction Crystallizable was deleted from the title.
- 5—Please indicate the correct surname (family name) of each author for indexing purposes.
- 6—Please verify that the mailing address and e-mail address for correspondence are correct as set.
- 7—If your article includes supplementary material, please confirm that all supplementary material is cited in the text.
- 8—If your article includes links to Web sites, please verify that the links are valid and will direct readers to the correct Web page.
- 9—PLEASE CONFIRM: You have chosen to pay \$2500 for members* or \$3000 for non-members, in addition to [Publication Charges](#) (Page, Color and Supplemental Data charges), to have the article made freely available online** immediately after publication through *The JI* Author Choice option.
*Corresponding Authors who are regular, emeritus, or honorary AAI members in good standing on the date of manuscript acceptance. **In addition to being freely available on *The JI* web site immediately upon publication, under *The JI* Author Choice option AAI will also deposit the published version of the article to PubMed Central for availability at the time of publication.
- 10—Please confirm that the author contribution footnote is correct as presented.
- 11—Please confirm that all of the abbreviations and expansions are correct as they appear in the abbreviations footnote. If any changes are needed, please ensure that the abbreviations and their expansions in the footnote are consistent with those that are used in the text.
- 12—Please confirm that “HEK” and “CHO” have been expanded correctly in the abstract or amend as needed.
- 13—Please check the proof carefully throughout to verify that edits have preserved your intent.
- 14—Any alternations between capitalization and/or italics in genetic nomenclature have been retained per the original manuscript. Please confirm that all genetic nomenclature has been formatted properly throughout.

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

2

- 15—Please confirm that “ADCC” has been expanded correctly in the sentences beginning “More detailed studies. . .” and “For example, the. . .” (in the next paragraph) or amend as needed.
- 16—Please confirm that “FDA” has been expanded correctly in the sentence beginning “For example, the. . .” or amend as needed.
- 17—Please expand “Man₉GlcNA₂” at its only appearance in the text per journal style, unless you are referring to a gene, protein, cell line, chemical, or designation (in the sentence beginning “For example, DC-SIGN. . .”).
- 18—Please confirm that “HA” and “HEK” have been expanded correctly in the sentences beginning “Two such hypersialylated. . .” and “Previous detailed *N*-glycans. . .” (in the next paragraph), respectively, or amend as needed.
- 19—Please confirm that “FDA” has been expanded correctly in the sentence beginning “Although CHO cells. . .” or amend as needed.
- 20—Please confirm that “Neu5Gc” and “Neu5Ac” have been expanded correctly in the paragraph beginning “CHO cell-based. . .” or amend as needed.
- 21—Please expand “CMP” at its only appearance in the text per journal style, unless you are referring to a gene, protein, cell line, chemical, or designation (in the sentence beginning “Humans do not. . .”).
- 22—In the *Materials and Methods* section and throughout, please confirm that all supplier names and product names are correct as edited.
- 23—The original Ref. 40 was a duplicate of Ref. 22, so the duplicate reference was deleted and the original Refs 41 to 60 were renumbered as Refs. 40 to 59. Please check all text citations for Refs. 40 to 59 against the References list to ensure that the renumbering was done properly.
- 24—Per journal style, “SE” is a standard abbreviation that may only be used to represent “standard error”; all instances of “SE” that are meant to represent “size exclusion” have been expanded throughout. Please confirm or amend as needed.
- 25—Please confirm that “clec,” “MBL,” and “MMR” have been expanded correctly in the sentence beginning “The same ELISA. . .” or amend as needed.
- 26—Please confirm that “F(ab')₂” is correct as edited in the sentence beginning “Binding of the. . .” or amend as needed.
- 27—Fig. 3 was not cited in the *Results* section, so a temporary citation has been added in the sentence beginning “Two panels of. . .” If this citation is incorrect, please add a correct citation of Fig. 3 after the first citation of Fig. 2 and before the first citation of Fig. 4 in the *Results*.

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

3

- 28—Per journal style, all instances of “E” notation should be converted to standard scientific notation; please confirm or amend the scientific notation in Tables I and II. Also, please expand “M,” “R_{MAX},” and “RU²” in the legends of Tables I and II unless you are referring to genes, proteins, cell lines, chemicals, strains, or designations. In addition, please confirm that “SPR” has been expanded correctly in the legends of Tables I and II or amend as needed.
- 29—Brackets are not used in Tables I and II, but parentheses do appear. Should the word “brackets” in the legends for Tables I and II be changed to “parentheses”?
- 30—Per journal guidelines, all figures must be cited in numerical order in the *Results* section, so temporary citations of Figs. 10 and 11 have been added in the sentence beginning “Both the D221N/C575A. . .” If this citation is incorrect, please add correct citations in numerical order for Figs. 10, 11, and 12 in the *Results* section.
- 31—Please confirm that “GlcNAc,” “GalNAc,” and “lacNAc” have been expanded correctly in the paragraph beginning “In these mutants. . .” or amend as needed.
- 32—Please confirm that “NA” has been expanded correctly in the sentence beginning “We do not yet. . .” or amend as needed.
- 33—Please confirm that “MDCK” has been expanded correctly in the sentence beginning “Thus, we were surprised. . .” or amend as needed.
- 34—A response to this query is REQUIRED: Please confirm that all potential conflicts of interest have been disclosed.
- 35—Please confirm that all publication details for Refs. 6, 12, and 17 are correct, including for the errata.
- 36—Is it correct that Ref. 14 has only one page? If not, please add an end page number, or replace the page number with a DOI number.
- 37—The original Ref. 40 was a duplicate of Ref. 22, so the duplicate reference was deleted and the original Refs 41 to 60 were renumbered as Refs. 40 to 59. Please check all text citations for Refs. 40 to 59 against the References list to ensure that the renumbering was done properly. Also, is it correct that Ref. 40 has only one page? If not, please add an end page number, or replace the page number with a DOI number.
- 38—Please confirm that the page number for Ref. 43 is correct as edited or amend as needed.
- 39—Is it correct that Ref. 55 has only one page? If not, please add an end page number, or replace the page number with a DOI number.
- 40—If your article includes figures, please check the figures in your proof carefully. If any changes are needed, please provide a revised figure file.

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

4

- 41—Please confirm that “MMR” has been expanded correctly in the legend for Fig. 3 or amend as needed.
- 42—For technical reasons, supplementary figures cannot be referred to without a specific number, so a general mention has been changed in the sentence beginning “The types of glycans. . .” If this citation is incorrect, please amend with the correct figure numbers.
- 43—Please provide a high quality tif, eps, or pdf (or if needed, PowerPoint) file for Fig. 8. If you’re able to provide the text and line art in vector format, this will ensure high quality at all sizes. If you built the figure using a vector application like PowerPoint, please send us that source file from the original application used. For nonvector figures, please use your source file for the image and recreate the figure if needed, being sure to maintain high quality resolution while processing. If you’re having difficulty seeing the low quality of the file, please enlarge it to at least three times the size it will be in publication.
-
-

Key Points

- Choice of cell line is critical for functional glycosylation of human IgG1-Fc.
- Sialylated IgG1-Fc monomers block influenza B only when made by CHO-K1 cells.